Microscopic photo from National Cancer Institute

Business group

Life sciences

HGF’s life sciences attorneys understand the challenges associated with commercially focused IP management and can advise on the pertinent issues, from invention conception through to patent term extension, to maximise the value of intellectual property.

Lady looking into test tube

As one of Europe’s largest groups of specialist life science attorneys, HGF has the wealth of technical and legal expertise to deliver truly global, commercially-focused strategies.

From protecting new research from Europe’s most prestigious universities, to high-profile oppositions for international healthcare companies on market-leading technologies, the team possesses in-depth legal experience. Particular technical expertise within the group covers the fields of foodtech, microbiome for therapeutic purposes, cell and gene therapy, bioinformatics, agritech, gene editing, and personalised medicine.

In addition, our life sciences attorneys work closely with our IP lawyers in relation to life cycle agreements such as MTAs, R&D collaborations, companion diagnostics, IP licensing, clinical trials through to commercial manufacturing and supply, and litigation.

Latest updates

Building to Survive: Designing Life Sciences Patent Portfolios to Withstand a Challenge

The strongest life sciences IP strategies are not designed simply just to obtain a series of patents. They are designed around the challenges those patents may have to withstand five, …

Read article

HGF Presents - Protecting Plant Innovation

In this video, we explore the statutory and regulatory barriers to the patentability of plant-related inventions in the US and Europe, before considering the landscapes further afield. Given the divergent …

Read article
Event - 12th November 2026

HGF Partners with PPTI for 'Designing Foods for Healthy Aging' Webinar

As healthy aging, metabolic health and weight management rise up the consumer agenda, food and nutrition businesses are increasingly looking beyond traditional product development and towards solutions that deliver measurable …

Event details

Basel Seminar: Seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU

Venue – Der Teufelhof Basel, Switzerland We are pleased to invite you to our seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU. …

Read article

Where Does the Real IP Value Lie in AI-Enabled Life Sciences?

After attending the BioTechX conference in Basel last week, talking to people working across pharma, biotech, AI, software, laboratory automation and data management, my main takeaway was clear: the conversation …

Read article

When AI Designs the Ingredient: Who Controls the Data, the Model and the Discovery?

AI-enabled discovery has drawn significant attention in pharmaceutical R&D, but its impact is extending into other industries, across ingredients, food, flavour, fragrance and industrial biotechnology. As AI models advance, the …

Read article

Protecting the AI Drug Discovery Ecosystem: Building an IP Stack Around Targets, Molecules and Medicines

Despite the considerable costs and effort in target identification, candidate generation, selection and advancement to clinical trials, 90% of candidates that enter clinical trials during drug discovery fail (Sun D, …

Read article

Agritech Thymes: UK-EU SPS agreement – what does it mean for plant breeders?

Since Brexit, the UK agrifood sector has faced difficulties, largely due to the requirement for additional certifications and controls, such as phytosanitary certificates and border checks. This has had a …

Read article